Fig. 5From: Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literatureThe location of HER2 mutations and corresponding targeted therapies in NSCLC, as well as the progression-free survival after treatment. NA means to have a clinical effect but no specific PFS. PFS refers to the mPFS in dacomitinib treatment of HER2 mutationsBack to article page